Organization
Roche Innovation Center
1 abstract
1 poster
Abstract
First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.Org: KSQ Therapeutics, Cambridge, MA, Roche Pharma Research and Early Development, Roche Innovation Center, Dana-Farber Cancer Institute, Hackensack University Medical Center,